GENFIT (GNFT) Competitors $3.84 +0.12 (+3.08%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. QURE, AVXL, IMNM, GYRE, PHAT, VIR, CRON, REPL, PHAR, and XERSShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include uniQure (QURE), Anavex Life Sciences (AVXL), Immunome (IMNM), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Vir Biotechnology (VIR), Cronos Group (CRON), Replimune Group (REPL), Pharming Group (PHAR), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors uniQure Anavex Life Sciences Immunome Gyre Therapeutics Phathom Pharmaceuticals Vir Biotechnology Cronos Group Replimune Group Pharming Group Xeris Biopharma uniQure (NASDAQ:QURE) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Does the media favor QURE or GNFT? In the previous week, uniQure had 8 more articles in the media than GENFIT. MarketBeat recorded 9 mentions for uniQure and 1 mentions for GENFIT. GENFIT's average media sentiment score of 1.87 beat uniQure's score of -0.50 indicating that GENFIT is being referred to more favorably in the news media. Company Overall Sentiment uniQure Neutral GENFIT Very Positive Do insiders & institutionals hold more shares of QURE or GNFT? 78.8% of uniQure shares are held by institutional investors. Comparatively, 2.2% of GENFIT shares are held by institutional investors. 4.8% of uniQure shares are held by company insiders. Comparatively, 4.2% of GENFIT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, QURE or GNFT? uniQure has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Is QURE or GNFT more profitable? GENFIT has a net margin of 0.00% compared to uniQure's net margin of -1,077.05%. GENFIT's return on equity of 0.00% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,077.05% -483.87% -34.28% GENFIT N/A N/A N/A Do analysts rate QURE or GNFT? uniQure currently has a consensus price target of $37.82, suggesting a potential upside of 166.89%. GENFIT has a consensus price target of $13.00, suggesting a potential upside of 238.10%. Given GENFIT's stronger consensus rating and higher probable upside, analysts clearly believe GENFIT is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, QURE or GNFT? GENFIT has higher revenue and earnings than uniQure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M28.62-$239.56M-$4.39-3.23GENFIT$67.00M2.87$1.63MN/AN/A SummaryGENFIT beats uniQure on 9 of the 15 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.24M$2.88B$5.52B$8.87BDividend YieldN/A2.70%5.36%4.13%P/E RatioN/A21.6626.5019.82Price / Sales2.87267.10410.19110.66Price / Cash51.6141.2925.8827.49Price / Book2.567.277.945.39Net Income$1.63M-$55.05M$3.15B$248.34M7 Day Performance-0.13%-0.47%1.08%1.25%1 Month Performance-12.21%6.59%5.34%5.41%1 Year Performance-3.88%0.42%32.80%18.07% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT2.2575 of 5 stars$3.85+3.1%$13.00+238.1%+3.2%$192.24M$67.00M0.00120Gap DownQUREuniQure2.0464 of 5 stars$13.95-1.8%$37.82+171.1%+211.2%$778.36M$27.12M-3.18500AVXLAnavex Life Sciences3.8528 of 5 stars$9.30+2.3%$44.00+373.1%+118.5%$776.03MN/A-16.9140IMNMImmunome2.2324 of 5 stars$8.74-0.1%$23.33+167.0%-23.1%$761.36M$10.94M-2.7540GYREGyre Therapeutics0.3094 of 5 stars$7.77-3.7%N/A-38.4%$756.62M$105.76M388.6940PHATPhathom Pharmaceuticals3.727 of 5 stars$9.47-9.1%$17.50+84.8%-6.9%$727.46M$55.25M-1.81110Positive NewsHigh Trading VolumeVIRVir Biotechnology3.4004 of 5 stars$5.05-3.4%$32.86+550.6%-43.4%$722.98M$74.21M-1.20580News CoveragePositive NewsCRONCronos Group2.2342 of 5 stars$1.87+0.5%N/A-18.0%$717.37M$117.61M14.39450REPLReplimune Group3.9815 of 5 stars$9.23-0.4%$20.83+125.7%+3.2%$714.59MN/A-3.01210PHARPharming Group2.9323 of 5 stars$10.49+0.3%$30.00+186.1%+27.9%$710.92M$297.20M-52.42280Positive NewsXERSXeris Biopharma4.0768 of 5 stars$4.64+2.9%$6.25+34.7%+107.6%$705.29M$203.07M-15.47290 Related Companies and Tools Related Companies uniQure Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Gyre Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Vir Biotechnology Alternatives Cronos Group Alternatives Replimune Group Alternatives Pharming Group Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
